Insmed Incorporated (NASDAQ:INSM) Stock Position Cut by Soros Fund Management LLC

Soros Fund Management LLC lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 4.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 455,089 shares of the biopharmaceutical company’s stock after selling 23,512 shares during the period. Soros Fund Management LLC’s holdings in Insmed were worth $31,419,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Darwin Global Management Ltd. lifted its holdings in shares of Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock worth $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors lifted its holdings in shares of Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after acquiring an additional 593,206 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after purchasing an additional 273,759 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on INSM shares. Bank of America upped their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Tuesday, April 22nd. Wells Fargo & Company raised their price target on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $94.00.

Insmed Stock Up 0.2 %

INSM stock opened at $69.86 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market capitalization of $12.70 billion, a price-to-earnings ratio of -12.50 and a beta of 1.07. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The stock has a fifty day moving average of $74.10 and a 200-day moving average of $73.54.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. As a group, equities research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 6,830 shares of the company’s stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company’s stock, valued at approximately $16,412,107.84. This represents a 2.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 471,797 shares of company stock valued at $37,621,239. Company insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.